Form 4: Twist Bioscience Chief Accounting Officer Sells Shares to Cover Tax Obligations

Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, sold 225 shares of common stock at $31.75 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), disposed of 225 shares of common stock.
• The transaction occurred on June 6, 2025, with shares sold at a price of $31.75 per share.
• The sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to fund tax withholding obligations associated with the vesting of Restricted Stock Units.
• This transaction was not a discretionary trade by the Reporting Person.
• Following the reported transaction, Mr. Werner beneficially owns 49,966 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not reflect a voluntary decision by the insider to sell shares.

Positives

• The transaction is a non-discretionary 'sell to cover' for tax obligations, indicating a standard process for equity compensation rather than a voluntary sale by management.

Negatives

• The sale, while non-discretionary, reduces the direct beneficial ownership of common stock by a key executive.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' for tax purposes, which is common practice across all industries, including biotechnology, when restricted stock units vest. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by an executive for tax purposes is a routine event and is unlikely to have a significant direct impact on existing shareholders. It does not signal a change in management's confidence in the company.

Key Dates

Keywords

Twist Bioscience, TWST, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Equity Compensation, Biotechnology, Synthetic Biology